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Semaphorin 3A: A Potential Target
for Low Back Pain
Pengbin Yin †, Houchen Lv †, Lihai Zhang, Licheng Zhang* and Peifu Tang*
Department of Orthopedics, Chinese PLA General Hospital, Beijing, China
Low back pain is a common disorder. Pathological innervation and intervertebral disc
degeneration are two major factors associated with this disease. Semaphorin 3A,
originally known for its potent inhibiting effect on axonal outgrowth, is recently found
to correlate with disease activity and histological features in some skeletal disorders.
Based on its effects on innervation and vascularization, as well as enzyme secretion, we
presume that semaphorin 3A may act as a potential target for low back pain.
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INTRODUCTION
Low back pain (LBP) is a common disorder. Around 60% of the adult population suffers from
back discomfort at some point in their lifetime (Hoy et al., 2012; Campbell and Colvin, 2013).
However, a definite pathological cause to this sickness is still unknown. Prior research has reported
various potential factors, which may be associated with back pain, such as mechanical changes,
low pH throughout the disc, disc degeneration, cytokines etc. Anatomically, it has been proposed
that degenerative joint disease and intervertebral disc degeneration are the most common factors.
In addition, pathological innervation into the degenerative intervertebral disc is said to be closely
related with pain of intervertebral disc origin (Luoma et al., 2000; Cheung et al., 2009; García-
Cosamalón et al., 2010; Miyagi et al., 2014). Thus, most therapeutic research on low back pain
focuses on inhibiting neural invasion and delaying disc degradation (Mantyh, 2014; Vasiliadis et al.,
2014; Sakai and Grad, 2015).
Semaphorin 3A, originally known for its potent inhibition of axonal outgrowth, has been found
to play pivotal roles in several other systems (Luo et al., 1993; Barresi et al., 2009; Shim et al.,
2013; van Gils et al., 2013). Notably, several recent studies have suggested that the expression
of semaphorin 3A and its receptors (neuropilins) correlates with disease activity and histological
features in some skeletal disorders (Hayashi et al., 2012; Negishi-Koga and Takayanagi, 2012;
Fukuda et al., 2013; Takagawa et al., 2013). Previous research has demonstrated that semaphorin 3A
is associated with innervation and vascularization, enzyme secretion, and cartilage development in
skeletal tissues (Gomez et al., 2005; Okubo et al., 2011; Fukuda et al., 2013). These effects contribute
to physiological and pathological alteration of the skeletal system. Further research also indicates
the important role of enzyme secretion in disc degradation (Canbay et al., 2013; Xu et al., 2014).
Since semaphorin 3A has been proven to be involved in both processes, we question that if there is
any correlation between semaphorin 3A and low back pain.
HYPOTHESIS
Based on the effects of semaphorin 3A on innervation and vascularization, as well as on enzyme
secretion in the skeletal system, coupled with the understanding of pathophysiology of low back
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pain, we hypothesize that semaphorin 3A may be a potential
therapeutic target for low back pain.
EVALUATION OF THE HYPOTHESIS
It has been observed in both animal and human studies that
with the progression of degeneration, sensory nerve fibers—
which require a low level of chemical and mechanical stimuli to
trigger pain—begin to innervate normally anural and avascular
areas (Freemont et al., 1997; Miyagi et al., 2014). Research by
Mantyh et al. showed that the administration of anti-nerve
growth factors dramatically block the sprouting of these fibers,
therefore significantly inhibited pain in mice (Mantyh et al.,
2010). Therefore, an approach to inhibit pathological neural and
vascular innervation in degenerative vertebral discs represents a
new potential for pain management and treatment.
The mechanisms underlying the degeneration of
intervertebral discs along with aging are complex, though
MMP has been shown to play an important role. Research
showed that the expression of MMPs is positively related to the
severity of degeneration (Rutges et al., 2008; Xu et al., 2014).
Based on their catabolic biological activities, the function of
these enzymes is to maintain the integrity of the matrix by
cooperating with other factors that perform anabolic activities
(Le Maitre et al., 2007). However, in a pathological condition the
balance disrupts and can lead to excessive degradation of disc
components (Vo et al., 2013).
Semaphorin 3A, a prototypical class 3 secreted semaphorin,
is a potent inhibitor of axonal outgrowth in a specific subset
of sensory and sympathetic neurons and induces collapse
of their growth cones. Research by Sotonye et al. showed
that semaphorin 3A is highly expressed by healthy disc cells
and decreased significantly in degenerate samples (Tolofari
et al., 2010). Considering its inhibition of axonal outgrowth,
semaphorin 3A may act as a biological barrier against neuronal
ingrowth within healthy intervertebral disc. In addition, mRNA
for semaphorin 3A receptors (neuropilins) was identified in
healthy and degenerate tissues (Tolofari et al., 2010). Neuropilins
have also been confirmed to bind to vascular endothelial growth
factor (VEGF), which is a key regulator of normal and pathologic
angiogenesis (Dai and Rabie, 2007). As VEGF and class 3
semaphorins compete for binding to neuropilins, reduction
of semaphorin 3A may lead to increased binding of VEGF.
Furthermore, binding of neuropilins to VEGF has been shown
to result in promotion of the migration, proliferation, and tube
formation of endothelial cells (Bates et al., 2003; Dai and Rabie,
2007; Roskoski, 2007; Staton et al., 2007). This process provides
chemoattractive cues for vascular innervation, which may be
associated with vascularization in degenerated intervertebral
disc. All in all, semaphorin 3A is a potent inhibitor of both
pathological innervation and vascular proliferation.
Research on lung cancer has further shown a negative
correlation between protein expression levels of semaphorin 3A
and MMP-14 (Zhou et al., 2014). In neurons, semaphorin 3A
was also shown to consistently reduce MMP-3 expression and
activity (Gonthier et al., 2009). Recent research on osteoarthritic
cartilage has also shown that semaphorin 3A inhibited VEGF165-
induced overexpression of MMPs (Okubo et al., 2011). These
findings demonstrate the potential role of semaphorin 3A in
negatively regulating MMP secretion. Although there is no
direct evidence showing a relationship between the expression
of MMPs and semaphorin 3A in patients with low back
pain, the observations in other tissues provide some clues on
the effects of semaphorin 3A on degenerative intervertebral
discs.
Therefore, based on the potent effects of semaphorin 3A on
repelling nerve ingrowth and vascular proliferation, as well as its
negative regulation of MMPs, we hypothesize that semaphorin
3A may be a potential therapeutic target for low back pain.
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